The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al

Arthritis Rheum. 2009 Nov 15;61(11):1616-7; author reply 1617-8. doi: 10.1002/art.24821.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antirheumatic Agents / economics*
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / economics*
  • Cost-Benefit Analysis
  • Humans
  • Quality-Adjusted Life Years

Substances

  • Antirheumatic Agents